Related Experiment Video

Updated: May 20, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Natural-agent mechanisms and early-phase clinical development

Janet L Wang1, Kathryn A Gold, Scott M Lippman

  • 1Baylor College of Medicine, Houston, TX, USA.

Topics in Current Chemistry
|August 2, 2012
PubMed

Insights

Chemoprevention research is advancing with targeted trial designs and biomarkers to identify effective cancer prevention agents. This approach promises to reverse negative trends and enable personalized cancer prevention strategies.

Area of Science:

  • Oncology
  • Preventive Medicine
  • Molecular Biology

Background:

  • Chemoprevention research has faced challenges with large trials in unselected populations yielding negative results.
  • Recent advances in understanding carcinogenesis and molecular signaling pathways offer new opportunities.
  • The focus is shifting towards personalized approaches in cancer prevention.

Purpose of the Study:

  • To review novel strategies in cancer chemoprevention research.
  • To highlight promising natural and synthetic agents and their molecular targets.
  • To discuss the role of biomarkers in predicting treatment efficacy for personalized cancer chemoprevention.

Main Methods:

  • Review of current literature on chemoprevention trial designs.
  • Analysis of molecular targets and signaling pathways in cancer development.
  • Examination of natural and synthetic agents, including epigallocatechin gallate, indole-3-carbinol, myo-inositol, and deguelin.
  • Discussion of biomarker identification for predicting agent efficacy.

Main Results:

  • Novel trial designs, including Phase 0 studies, are improving the focus of chemoprevention research.
  • Identification of molecular targets and predictive biomarkers is crucial for success.
  • Several natural agents show promise, with ongoing research into their efficacy and biomarkers.

Conclusions:

  • Personalized cancer chemoprevention is becoming a reality through targeted approaches.
  • Biomarkers are essential for identifying individuals likely to benefit from specific chemopreventive agents.
  • Early clinical development of natural agents holds significant promise for future cancer prevention strategies.

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).